NGNE
Neurogene Inc.
Key Financials
Net Income
$-90351000
↓ 20.2%
Revenue
$0
↓ 100.0%
Total Assets
$288.6M
↓ 14.0%
EPS (Diluted)
$-4.24
↑ 0.9%
Shareholders' Equity
$264.9M
↓ 14.7%
Total Liabilities
$23.7M
↓ 6.5%
Cash & Equivalents
$103.8M
↓ 24.0%
Operating Income
$-103328000
↓ 25.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4/A | 6/16/2026 | View on SEC |
| 4/A | 6/16/2026 | View on SEC |
| 4/A | 6/16/2026 | View on SEC |
| 3/A | 6/16/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NGNE |
| Company Name | Neurogene Inc. |
| CIK | 1404644 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (877) 237-5020 |